Welcome to our dedicated page for Havn Life Scienc news (Ticker: HAVLF), a resource for investors and traders seeking the latest updates and insights on Havn Life Scienc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Havn Life Scienc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Havn Life Scienc's position in the market.
Havn Life Sciences Inc. has completed the acquisition of GCO Packaging and Manufacturing Ltd. for 6,000,000 common shares. This strategic move aims to enhance Havn Life's retail strategy by expanding its product portfolio and entering new Natural Health Product categories.
The 16,000 square foot Facility is certified USDA Organic and Canadian Organic, thereby facilitating efficient production and distribution. The acquisition also allows for reduced reliance on third-party manufacturers. CEO Tim Moore emphasizes the potential for launching a range of innovative products this spring.
Havn Life Sciences (CSE:HAVN, OTC PINK:HAVLF) has signed a letter of intent with Hypha Wellness Jamaica Psilocybin to collaborate on the research and development of standardized psilocybin products. This partnership aims to enhance the production of medical psilocybin, crucial for addressing PTSD and other trauma-related disorders. The company is also establishing a production facility in Jamaica, which will help optimize production methods and potentially create a reliable supply chain for researchers globally. Havn Life's commitment includes supplying safe, quality-controlled psilocybin medicine.
Havn Life Sciences (CSE:HAVN, OTC PINK:HAVLF) announced that CEO Tim Moore will present at the Zooming with LD event on March 24th, 2020, at 8:00 AM PT / 11:00 AM ET. The presentation will focus on the company's mission to standardize the extraction of psychoactive compounds and develop natural health care products. Following the presentation, investors can engage in 1:1 meetings with Moore. This event serves as a platform for innovative companies in the microcap sector, highlighting the potential of psychedelic medicine.
Havn Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF) has appointed Jenna Pozar as Chief Operating Officer to lead sales, marketing, e-commerce, and logistics for Havn Retail. With 18 years of experience, she previously founded Pozar Health Solutions, a leading agency in natural health products. Havn Retail's product line is set to launch this spring at Nesters Market and online. The company focuses on the standardized extraction of psychoactive compounds and natural healthcare products, aiming to unlock human potential through research.
Havn Life Sciences Inc. will host a webcast investor presentation on March 3, 2021, at 2:00 p.m. EST. CEO Tim Moore will present an overview of the company’s business strategy, including plans for Havn Labs and Havn Retail, as well as product launches and financing goals for the upcoming quarter. Investors can interact directly during the Q&A session. Pre-registration is required at this link.
Archived content will also be available through the same link.
Havn Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF, FSE:5NP) has achieved DTC eligibility for its common shares in the U.S., allowing for streamlined electronic clearing and settlement. This milestone is expected to enhance visibility and accessibility for investors, enabling broader trading across many brokerage firms. Havn Life remains committed to the standardized extraction of psychoactive compounds and the development of natural healthcare products. CEO Tim Moore emphasizes that this move will facilitate a seamless trading process for shareholders.
Havn Life Sciences Inc. (CSE:HAVN, OTC PINK:HAVLF) announced the immediate departure of President Ms. Barinder Rasode and the appointment of CEO Mr. Tim Moore as a director. Rasode expressed confidence in the company's future, having established a solid team. Chairman Vic Neufeld praised Rasode's contributions and emphasized the strength of the company's leadership under Moore, who has a strong biotech background. The company, focused on extracting psychoactive compounds for health products, is positioned for growth.
Havn Life Sciences (OTC PINK: HAVLF) has announced the launch of seven natural health supplements designed to enhance memory, brain function, and overall wellness while combating stress. These products, which include various formulations featuring adaptogens and antioxidants, are slated for release in 2021 and have received approval from Health Canada. The company emphasizes its commitment to supporting human optimization through evidence-informed research and quality-controlled extraction of psychoactive compounds.